Nxera Pharma receives AbbVie milestone payment
Analysis based on 9 articles · First reported Apr 20, 2026 · Last updated Apr 20, 2026
The market is positively impacted by the progress in neurological disease research, as it signals potential for new treatments. Nxera Pharma's stock may see a positive reaction due to the milestone payment and validation of its platform, while AbbVie Inc. benefits from advancing its pipeline.
Nxera Pharma Co., Ltd. announced it has received a US$10 million milestone payment from AbbVie Inc. This payment is a result of achieving the third R&D milestone under their multi-target discovery collaboration focused on neurological diseases. The collaboration, initiated in 2022, leverages Nxera Pharma's NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GPCRs). This specific milestone relates to the identification of validated and differentiated 'hit' molecules against a neurology target. Under the agreement, Nxera Pharma is eligible for up to US$40 million in near-term research milestones and up to US$1.2 billion in potential option, development, and commercial milestones, plus tiered royalties on global sales. Christopher Cargill, President and CEO of Nxera Pharma, emphasized the importance of this milestone in advancing their pipeline and addressing unmet needs in neurological disease.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard